Lataa...

PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB(1) receptors with hypophagic effects in rats

BACKGROUND AND PURPOSE: Rimonabant (Acomplia(TM), SR141716A), a cannabinoid CB(1) receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB(1) antagonist with a different pharmacological mechanis...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Horswill, J G, Bali, U, Shaaban, S, Keily, J F, Jeevaratnam, P, Babbs, A J, Reynet, C, Wong Kai In, P
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Publishing Group 2007
Aiheet:	Research Papers
Linkit:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2190018/ https://ncbi.nlm.nih.gov/pubmed/17592509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0707347
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB(1) receptors with hypophagic effects in rats

Samankaltaisia teoksia